Literature DB >> 24022503

Premenopausal bone health: osteoporosis in premenopausal women.

Alice Abraham1, Adi Cohen, Elizabeth Shane.   

Abstract

This article will discuss the diagnosis of osteoporosis in premenopausal women and the evaluation and management of those with low-trauma fractures and/or low bone mineral density. As secondary causes (glucocorticoid excess, anorexia nervosa, premenopausal estrogen deficiency, and celiac disease) are commonly the underlying cause of osteoporosis in this population, treatment of the underlying condition should be the focus of management. Additional management options, generally reserved for those with major or multiple fractures and/or ongoing bone loss, will also be described.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24022503      PMCID: PMC4139057          DOI: 10.1097/GRF.0b013e3182a8ae55

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  46 in total

1.  Bisphosphonates in pregnancy and lactation-associated osteoporosis.

Authors:  S M O'Sullivan; A B Grey; R Singh; I R Reid
Journal:  Osteoporos Int       Date:  2006-04-27       Impact factor: 4.507

2.  Treatment of glucocorticoid-induced osteoporsis.

Authors:  Gherardo Mazziotti; Andrea Giustina; Ernesto Canalis; John P Bilezikian
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-02       Impact factor: 5.346

Review 3.  The role of exercise in the treatment of osteoporosis.

Authors:  Mehrsheed Sinaki; Michael Pfeifer; Elisabeth Preisinger; Eiji Itoi; René Rizzoli; Steven Boonen; Piet Geusens; Helmut W Minne
Journal:  Curr Osteoporos Rep       Date:  2010-09       Impact factor: 5.096

Review 4.  Premenopausal bone health assessment.

Authors:  E Michael Lewiecki
Journal:  Curr Rheumatol Rep       Date:  2005-03       Impact factor: 4.592

5.  The annual incidence and seasonal variation of fractures of the distal radius in men and women over 25 years in Dorset, UK.

Authors:  Paul W Thompson; Julia Taylor; Adrian Dawson
Journal:  Injury       Date:  2004-05       Impact factor: 2.586

6.  Peripheral bone mineral density in patients with distal radial fractures.

Authors:  C A Wigderowitz; T Cunningham; D I Rowley; P A Mole; C R Paterson
Journal:  J Bone Joint Surg Br       Date:  2003-04

7.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

8.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

Authors:  T J Powles; T Hickish; J A Kanis; A Tidy; S Ashley
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

9.  Clinical characteristics and etiologic factors of premenopausal osteoporosis in a group of Spanish women.

Authors:  Pilar Peris; Núria Guañabens; Ma Jesús Martínez de Osaba; Ana Monegal; Luisa Alvarez; Francesca Pons; Inmaculada Ros; Dacia Cerdá; José Muñoz-Gómez
Journal:  Semin Arthritis Rheum       Date:  2002-08       Impact factor: 5.532

Review 10.  Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density.

Authors:  M Sagsveen; J E Farmer; A Prentice; A Breeze
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  2 in total

Review 1.  Premenopausal Osteoporosis.

Authors:  Adi Cohen
Journal:  Endocrinol Metab Clin North Am       Date:  2016-11-24       Impact factor: 4.741

2.  Whole exome sequencing reveals potentially pathogenic variants in a small subset of premenopausal women with idiopathic osteoporosis.

Authors:  Adi Cohen; Joseph Hostyk; Evan H Baugh; Christie M Buchovecky; Vimla S Aggarwal; Robert R Recker; Joan M Lappe; David W Dempster; Hua Zhou; Mafo Kamanda-Kosseh; Mariana Bucovsky; Julie Stubby; David B Goldstein; Elizabeth Shane
Journal:  Bone       Date:  2021-11-04       Impact factor: 4.398

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.